Stock comparison
Halozyme Therapeutics
TG Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
TGTX
TG Therapeutics
Market cap
$6.51B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | TGTX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 42D | HALO |
| Benjamin Graham | 73B | 54C | HALO |
| Philip Fisher | 55C | 50C | HALO |
| Peter Lynch | 43D | 84A | TGTX |
| Joel Greenblatt | 30F | 55C | TGTX |
| Charlie Munger | 70B | 44D | HALO |
| Terry Smith | 74B | 37D | HALO |
Side-by-side metrics
| Metric | HALO | TGTX |
|---|---|---|
| Market cap | $8.41B | $6.51B |
| P/E (TTM) | 24.0x | 13.3x |
| EV/EBIT | 10.2x | 55.3x |
| ROIC (TTM) | 23.65% | 11.13% |
| Gross margin | 81.24% | 83.04% |
| Net margin | 23.13% | 65.95% |
| Revenue CAGR 5y | 33.23% | 2.1% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- EV/EBIT10.2xvs 55.3x+82%
- ROIC (TTM)23.65%vs 11.13%+53%
- Debt / Equity1.0xvs 1.3x+26%
- Market cap$8.41Bvs $6.51B+23%
TGTX leads on
- Revenue CAGR 5y2.1%vs 33.23%+84%
- Net margin65.95%vs 23.13%+65%
- P/E (TTM)13.3xvs 24.0x+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.